Personalis, Inc.

PSNL

Precision medicineHealthcare diagnosticsGenomic analysis

$17.23vs prev close▼-1.15(-6.26%)

$4.6552W Range$18.89

88% from low

+5.51 (+46.77%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.73%

1M -0.09%p

Holding ETFs

1 ETFs

ARKG

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -14.5% · Market value -19.4% · Weight -0.09%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.07.16	SELL	ARKG	243,532	$15.58	$3.8M
26.07.15	SELL	ARKG	148,988	$15.79	$2.4M
26.07.14	SELL	ARKG	162,990	$15.03	$2.4M
26.07.13	SELL	ARKG	276,740	$15.04	$4.2M
26.07.10	SELL	ARKG	1,977	$14.07	$27.8K
26.07.09	SELL	ARKG	31,889	$14.65	$467.2K
26.07.08	SELL	ARKG	188,066	$14.11	$2.7M
26.07.07	SELL	ARKG	31,388	$13.98	$438.8K
26.03.12	SELL	ARKG	6,850	$6.59	$45.1K
26.03.11	SELL	ARKG	58,693	$7.95	$466.6K
26.02.27	SELL	ARKG	139,724	$9.06	$1.3M
26.01.12	BUY	ARKG	17,748	$8.57	$152.1K
26.01.09	BUY	ARKG	262,769	$8.10	$2.1M
26.01.08	BUY	ARKG	22,395	$8.38	$187.6K
26.01.05	BUY	ARKG	47,587	$8.02	$381.6K

07.16SELL

243,532

ARKGClose$15.58Est. total$3.8M

07.15SELL

148,988

ARKGClose$15.79Est. total$2.4M

07.14SELL

162,990

ARKGClose$15.03Est. total$2.4M

07.13SELL

276,740

ARKGClose$15.04Est. total$4.2M

07.10SELL

1,977

ARKGClose$14.07Est. total$27.8K

07.09SELL

31,889

ARKGClose$14.65Est. total$467.2K

07.08SELL

188,066

ARKGClose$14.11Est. total$2.7M

07.07SELL

31,388

ARKGClose$13.98Est. total$438.8K

03.12SELL

6,850

ARKGClose$6.59Est. total$45.1K

03.11SELL

58,693

ARKGClose$7.95Est. total$466.6K

02.27SELL

139,724

ARKGClose$9.06Est. total$1.3M

01.12BUY

17,748

ARKGClose$8.57Est. total$152.1K

01.09BUY

262,769

ARKGClose$8.10Est. total$2.1M

01.08BUY

22,395

ARKGClose$8.38Est. total$187.6K

01.05BUY

47,587

ARKGClose$8.02Est. total$381.6K

1 / 6

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

6,717,124

Portfolio Weight

0.73%

in ETF 5.48%

Est. Value

$91M

30D Net

-$16M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Hold

Analyst Targets

avg.

$13.88

vs Current ▼ -24.5% downside

Current$18.38

Low ~ High$10.00 ~ $16.25

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Lake Street

Hold

$16.25

-11.59%

—

Downgrade

2026-07-20

BTIG

Buy

$16.25

-11.59%

—

Maintain

2026-07-20

Needham

Hold

N/A

—

Downgrade

2026-07-20

Needham

Buy

$17.00

-7.51%

—

Maintain

2026-07-17

Morgan Stanley

Equal-Weight

$13.00

-29.27%

—

Maintain

2026-07-09

1 / 4

Avg Target

$13.88

vs Current ▼ -24.5% downside

Buy

5 analysts

Buy 3Hold 2

Low $10.00

Current $18.38

High $16.25

Firm	Position	Target	Upside	Close	Action	Date
Lake Street	Hold	$16.25	-11.59%	—	Downgrade	26.07.20
BTIG	Buy	$16.25	-11.59%	—	Maintain	26.07.20
Needham	Hold	N/A	N/A	—	Downgrade	26.07.20
Needham	Buy	$17.00	-7.51%	—	Maintain	26.07.17
Morgan Stanley	Equal-Weight	$13.00	-29.27%	—	Maintain	26.07.09

1 / 4

Price Information

Previous Close$16.88

Open$16.66

Day Range$16.62 - $18.89

52-Week Range$4.65 - $18.89

1-Year Change291.06%

Trading Volume

Volume7,980,055

Avg Volume (3mo)4,179,569

Valuation

Market Cap2.0B

Book Value$2.21

Shares Outstanding106,799,872

Financials

Revenue (TTM)69.7M

Net Income-107,179,000

EPS$-1.09

EBITDA-104,596,000

Profitability

P/E Ratio-

P/B Ratio8.31

Return on Equity (ROE)-50.32%

Return on Assets (ROA)-25.03%

Profit Margin-153.84%

EV/EBITDA-17.10

Beta2.29

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)81.66

Company Overview

Personalis, Inc. is a cancer genomics company that develops and markets advanced tests and services for cancer detection and monitoring. Their main products include liquid biopsy tests like NeXT Personal for minimal residual disease (MRD) detection and tissue-based services like ImmunoID NeXT for a multi-dimensional tumor analysis. These solutions are utilized by pharmaceutical companies for research and clinical trials, and by physicians for patient therapy selection and monitoring.

P/B

8.31

High valuation

ROE

-50.3%

Persistent loss

Beta

2.29

Extreme volatility

RSI(14)

81.7

Overbought

AI-generated summary. Not investment advice.

Personalis, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks